KR101674977B1 - 발현 벡터 - Google Patents

발현 벡터 Download PDF

Info

Publication number
KR101674977B1
KR101674977B1 KR1020107025821A KR20107025821A KR101674977B1 KR 101674977 B1 KR101674977 B1 KR 101674977B1 KR 1020107025821 A KR1020107025821 A KR 1020107025821A KR 20107025821 A KR20107025821 A KR 20107025821A KR 101674977 B1 KR101674977 B1 KR 101674977B1
Authority
KR
South Korea
Prior art keywords
bifidobacterium
plasmid
dna
protein
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107025821A
Other languages
English (en)
Korean (ko)
Other versions
KR20110021784A (ko
Inventor
유코 시마타니-시바타
히토미 시미즈
히로미 요네쿠라
Original Assignee
가부시키가이샤 아네로파마·사이엔스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 아네로파마·사이엔스 filed Critical 가부시키가이샤 아네로파마·사이엔스
Publication of KR20110021784A publication Critical patent/KR20110021784A/ko
Application granted granted Critical
Publication of KR101674977B1 publication Critical patent/KR101674977B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107025821A 2008-04-17 2009-04-16 발현 벡터 Expired - Fee Related KR101674977B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12452808P 2008-04-17 2008-04-17
US61/124,528 2008-04-17
PCT/JP2009/001768 WO2009128272A1 (en) 2008-04-17 2009-04-16 Expression vector

Publications (2)

Publication Number Publication Date
KR20110021784A KR20110021784A (ko) 2011-03-04
KR101674977B1 true KR101674977B1 (ko) 2016-11-10

Family

ID=40792658

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020107025821A Expired - Fee Related KR101674977B1 (ko) 2008-04-17 2009-04-16 발현 벡터
KR1020107025820A Expired - Fee Related KR101671283B1 (ko) 2008-04-17 2009-04-17 혐기성 질환을 위한 치료제
KR1020167022911A Ceased KR20160102584A (ko) 2008-04-17 2009-04-17 혐기성 질환을 위한 치료제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020107025820A Expired - Fee Related KR101671283B1 (ko) 2008-04-17 2009-04-17 혐기성 질환을 위한 치료제
KR1020167022911A Ceased KR20160102584A (ko) 2008-04-17 2009-04-17 혐기성 질환을 위한 치료제

Country Status (12)

Country Link
US (3) US8383398B2 (enExample)
EP (2) EP2274422B1 (enExample)
JP (3) JP5735804B2 (enExample)
KR (3) KR101674977B1 (enExample)
CN (2) CN102046791B (enExample)
CA (2) CA2721653C (enExample)
DK (2) DK2274422T3 (enExample)
ES (2) ES2628378T3 (enExample)
HU (2) HUE033561T2 (enExample)
PL (2) PL2274422T3 (enExample)
PT (2) PT2274422T (enExample)
WO (2) WO2009128272A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535939B2 (en) 2010-01-29 2013-09-17 Anaeropharma Science, Inc. Transfection vector
US20130095072A1 (en) * 2010-01-29 2013-04-18 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US8338162B2 (en) * 2009-04-17 2012-12-25 Anaeropharma Science, Inc. Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
WO2013008881A1 (ja) * 2011-07-13 2013-01-17 株式会社アネロファーマ・サイエンス 虚血性疾患治療薬
KR20170088866A (ko) 2014-12-03 2017-08-02 가부시키가이샤 아네로파마·사이엔스 공발현 플라스미드
KR101892722B1 (ko) * 2015-01-19 2018-08-28 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 허혈성 질환 치료제
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
WO2021038975A1 (ja) 2019-08-28 2021-03-04 株式会社アネロファーマ・サイエンス ダイアボディ型ＢｓＡｂを発現・分泌するビフィドバクテリウム属細菌
CN112999215B (zh) * 2019-12-20 2024-06-21 复旦大学 呋喃酮糖苷类化合物的应用
CN115400154A (zh) * 2022-08-10 2022-11-29 深圳未知君生物科技有限公司 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用
WO2024187069A1 (en) * 2023-03-08 2024-09-12 University Of Florida Research Foundation, Incorporated Engineering enterobacteria to site-specifically activate the anticancer prodrug 5-fluorocytosine for treating colon cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136107A1 (ja) * 2006-05-24 2007-11-29 Anaeropharma Science Inc. 遺伝子輸送担体作製方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713601D0 (en) * 1987-06-10 1987-07-15 Unilever Plc Fermentation
WO1991009131A1 (en) * 1989-12-20 1991-06-27 Valio Finnish Cooperative Dairies Association Cloning vector for use in lactic acid bacteria
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7008633B2 (en) * 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
KR100457879B1 (ko) * 2001-02-24 2004-11-18 주식회사 비피도 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법
PT2088193E (pt) 2004-11-24 2011-02-24 Anaeropharma Science Inc Novo vector vaivém
ES2548516T3 (es) * 2005-01-21 2015-10-19 The Research Foundation Of The State University Of New York Métodos para el tratamiento de la capsulitis adhesiva
EP1867714B1 (en) 2005-04-08 2013-09-18 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof
CA2646244A1 (en) * 2006-03-27 2007-10-04 Government Of The United States Of Americas, As Represented By The Secre Tetracycline compounds and methods of treatment
GB2439310A (en) * 2006-04-13 2007-12-27 Ambrozea Inc Fermentation residuals from genetically-modified microorganisms
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136107A1 (ja) * 2006-05-24 2007-11-29 Anaeropharma Science Inc. 遺伝子輸送担体作製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank Accession Number AB187597 (2005.03.05.)*

Also Published As

Publication number Publication date
CN102046190A (zh) 2011-05-04
EP2274422B1 (en) 2017-03-15
US20110110893A1 (en) 2011-05-12
KR20160102584A (ko) 2016-08-30
JP5514735B2 (ja) 2014-06-04
JP2011518112A (ja) 2011-06-23
EP2280717A1 (en) 2011-02-09
PT2280717T (pt) 2018-10-04
WO2009128275A9 (en) 2010-11-11
CA2721664A1 (en) 2009-10-22
CN102046791B (zh) 2013-09-18
CA2721653A1 (en) 2009-10-22
PT2274422T (pt) 2017-06-28
EP2274422A1 (en) 2011-01-19
CN102046791A (zh) 2011-05-04
JP6089025B2 (ja) 2017-03-01
US8470311B2 (en) 2013-06-25
ES2686080T3 (es) 2018-10-16
CA2721653C (en) 2018-03-20
CA2721664C (en) 2018-01-23
CN102046190B (zh) 2013-03-13
US20090264513A1 (en) 2009-10-22
WO2009128275A4 (en) 2010-02-18
JP2015091243A (ja) 2015-05-14
US20130122582A1 (en) 2013-05-16
DK2274422T3 (en) 2017-07-03
PL2280717T3 (pl) 2018-10-31
WO2009128272A1 (en) 2009-10-22
WO2009128275A1 (en) 2009-10-22
DK2280717T3 (en) 2018-09-10
KR20100134765A (ko) 2010-12-23
JP2011517929A (ja) 2011-06-23
PL2274422T3 (pl) 2017-09-29
EP2280717B1 (en) 2018-05-30
HUE039768T2 (hu) 2019-02-28
KR101671283B1 (ko) 2016-11-02
WO2009128272A4 (en) 2010-02-18
KR20110021784A (ko) 2011-03-04
US8383398B2 (en) 2013-02-26
WO2009128272A9 (en) 2010-11-11
HUE033561T2 (hu) 2017-12-28
JP5735804B2 (ja) 2015-06-17
ES2628378T3 (es) 2017-08-02

Similar Documents

Publication Publication Date Title
KR101674977B1 (ko) 발현 벡터
KR102853088B1 (ko) 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
CN114190093B (zh) 使用腺苷酸脱氨酶碱基编辑器破坏疾病相关基因的剪接受体位点，包括用于治疗遗传性疾病
CN110551713B (zh) 用于修饰梭状芽孢杆菌属细菌的优化的遗传工具
KR101823695B1 (ko) 신규 미생물 숙신산 생산자 및 숙신산의 정제
KR101850162B1 (ko) 형질전환용 플라스미드
AU2016308591B2 (en) Delivery vehicle
JP2022520081A (ja) アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法
CN100560724C (zh) 用于选择含有编码针对毒性分子的解毒剂蛋白的序列的重组克隆的方法
CN104838016A (zh) 用于识别相对于其野生型具有提高的特定代谢物细胞内浓度的细胞的方法,其中通过重组工程实现细胞的改变,以及用于制备相对于其野生型具有优化的特定代谢物产量的经基因修饰的生产细胞的方法,用于制备这种代谢物的方法,以及适合于此的核酸
EP1974037B1 (en) Linear vectors, host cells and cloning methods
CN116848235A (zh) 工程化t细胞
Bari et al. CRISPR–Cas10 assisted editing of virulent staphylococcal phages
CN113614229B (zh) 遗传修饰的梭菌属细菌、其制备和用途
CN114286857B (zh) 用于修饰细菌的优化的遗传工具
JP2022534437A (ja) 真核細胞への遺伝子編集システムの送達のための細菌プラットフォーム
KR20160147778A (ko) 항체 유전자의 발현·분비 시스템
GB2544957A (en) Modifying bacteriophage
EP0209204A1 (en) New vector plasmids, their construction and use, and microorganisms in which they are incorporated
KR20210109537A (ko) 아시네토박터 바우마니의 검출을 위한 비-복제 형질 도입 입자 및 형질 도입 입자 기반의 리포터 시스템
CN115404193A (zh) 重组微生物及其用于生产1,5-戊二胺的方法
CN116888266A (zh) 靶蛋白的生产方法
BR102014017026A2 (pt) método de obtenção do vetor de expressão, cassete de expressão, vetor de expressão e sistema de expressão para a produção constitutiva e secreção de proteínas heterólogas

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211105

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211105